EVKEEZA

Indicated For

Homozygous familial hypercholesterolemia (HoFH)

About This Medication

# myRARE Patient Support Program Patient Guide: How to Get EVKEEZA (evinacumab-dgnb) at Low or No Cost EVKEEZA (evinacumab-dgnb) is an FDA-approved intravenous medication used to lower **low-density lipoprotein cholesterol (LDL-C)** in adults and children aged 5 years and older with **homozygous familial hypercholesterolemia (HoFH)**, a rare genetic condition causing extremely high cholesterol levels that increase the risk of early heart disease.[1][5][9] The **myRARE Patient Support Program** from **Regeneron Pharmaceuticals, Inc.** helps eligible patients access EVKEEZA by covering out-of-pocket costs like copays, coinsurance, deductibles, and even providing free medication for up to 12 months for those who qualify.[1][2][5] ## About EVKEEZA and Why Assistance Matters EVKEEZA works differently from other cholesterol-lowering drugs. It is a monoclonal antibody that targets **angiopoietin-like 3 (ANGPTL3)**, a protein that regulates lipid metabolism, helping to reduce LDL-C, apolipoprotein B, and other lipids even in patients with HoFH who may not respond well to statins or other therapies.[1][5] Administered every four weeks via IV infusion at a certified infusion center or specialty pharmacy, EVKEEZA requires careful coordination, prior authorizations, and often high costs without support—potentially tens of thousands per year.[1][2] High costs can be a barrier, but myRARE bridges that gap. For **commercially insured patients**, the program offers up to **$25,000 per calendar year** in copay assistance, potentially reducing your out-of-pocket to $0. For **uninsured or underinsured patients**, free drug for up to 12 months is possible through the Patient Assistance Program (PAP).[1][5][6][9] Patient Navigators provide personalized help with insurance navigation, treatment logistics, appointment reminders, and resources to empower you throughout your journey.[1][2] ## Who Qualifies for myRARE? Eligibility depends on your insurance status and, for some paths, income. myRARE serves patients with HoFH prescribed EVKEEZA. - **Commercially insured (private insurance)**: No income requirements. If your plan covers EVKEEZA, you may get up to $25,000/year assistance for copays, deductibles, coinsurance, and administration fees.[1][6] - **Uninsured/underinsured**: Income-based eligibility for free EVKEEZA (up to 12 months). Typically up to **500% of the Federal Poverty Level (FPL)** for singles/couples, though exact thresholds vary—check current FPL at healthcare.gov.[5][6][8] - **Medicare Part B**: Limited eligibility; qualified patients can participate until **December 31 of the enrollment year**.[3][6] - **Not eligible**: Patients enrolled in **Medicaid, TRICARE, VA**, or where prohibited by law. Employer plans prohibiting assistance may also disqualify.[5][7] **myRARE's Patient Navigators** assess your situation confidentially and guide you to the best option, including for 'functionally uninsured' cases.[2][6] ## Income Eligibility Breakdown Income rules apply mainly to uninsured/underinsured patients seeking free drug via PAP. Commercially insured have **no income limits**.[1][6] Here's a general table based on program details (always verify current FPL as it updates annually): | Household Size | Max Income (500% FPL, approx. 2026 est.) | Notes | |---------------|-----------------------------------------|-------| | **Individual** | ~$73,000 | For uninsured PAP[8] | | **Couple** | ~$98,000 | For uninsured PAP[8] | | **Family of 3** | ~$124,000 | Income ≤500% FPL[8] | | **Family of 4** | ~$150,000 | Higher for larger families | *Notes: Figures are estimates; visit healthcare.gov for exact FPL. No income check for commercial copay assistance. Regeneron reserves right to adjust.*[3][6][8] ## Insurance Requirements - **Primary path**: **Commercial/private insurance** covering EVKEEZA (after prior authorization). - **Alternatives**: Uninsured/underinsured (income-qualified) or limited Medicare Part B. - **Exclusions**: Medicaid, TRICARE, VA, or government programs. Not valid where taxed/restricted.[5][7] Your Patient Navigator helps verify coverage, appeal denials, and handle prior authorizations.[2] ## Step-by-Step Application Process 1. **Contact myRARE**: Call **1-833-469-7273** (1-833-4my-RARE) or **1-877-EVKEEZA (1-877-385-3392), Option 1**, Mon-Fri 9AM-7PM ET. Or start online at **www.myRARE.com**.[2][3][6] 2. **Speak to a Patient Navigator/Access Coordination Educator (ACE)**: They'll review your insurance, income (if needed), and eligibility. Provide basic info verbally.[1][2] 3. **Gather Documents**: - Proof of income (pay stubs, tax returns). - Insurance cards (front/back). - Prescription drug cards. - Prior authorization approval/denial letters.[Program details] 4. **Enroll Online or by Phone**: Submit at myRARE.com (print confirmation). Consent to share health info with Regeneron for verification.[6][7] 5. **Approval & Copay Card**: If eligible, receive a copay card (digital/physical) for pharmacy/infusion use. For PAP, free drug ships.[1][5] **Reauthorization**: Required periodically—your Navigator will guide renewals.[Program details] ## Timeline and Delivery Processing time varies (not specified, typically days to weeks). Expect: - Initial review: 1-3 business days. - Full approval: After documents/PA verification. - Delivery: Via **specialty pharmacy** to your infusion center. Navigator coordinates scheduling.[1][2][Program details] Track via Navigator; get reminders. ## Alternatives if Denied - Appeal insurance denial with Navigator help. - Explore other Regeneron resources or independent foundations. - No biosimilars available.[Program details][2] - Discuss with doctor: Other HoFH therapies like lomitapide or mipomersen (if appropriate). ## Disclaimer This guide is for informational purposes based on available program details as of 2026. Eligibility, benefits, and terms subject to change without notice. Regeneron reserves rights to amend/terminate. Not valid where prohibited. Consult myRARE (1-833-469-7273) or healthcare provider for personalized advice. Does not guarantee coverage. Medicare patients: Limited to enrollment year-end.[1][3][6][7] (Word count: 1028)

Program information last verified: March 30, 2026